Bristol-Myers
Squibb Company (NYSE:BMY) today announced that it has completed the
previously announced planned acquisition of Flexus Biosciences, Inc.
The transaction includes full rights to F001287, Flexus’ lead
preclinical, small-molecule IDO1-inhibitor targeted for IND filing in
the second half of 2015 and an IDO/TDO discovery program that includes
its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A
newly formed entity established by the current shareholders of Flexus
will retain, from and after the closing, all non-IDO/TDO assets of
Flexus including those related to Flexus’ Phase 1 FLT3 and CDK4/6
inhibitor, its earlier stage small-molecule Treg cancer immunotherapy
programs, and its current personnel and facilities.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" relating to
the acquisition of Flexus by Bristol-Myers Squibb and the discovery,
development and commercialization of certain investigational compounds.
Such forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including factors that could
delay, divert or change any of them, and could cause actual outcomes and
results to differ materially from current expectations. No
forward-looking statement can be guaranteed. Among other risks, there
can be no guarantee that the expected benefits of the acquisition will
be realized. In addition, the compounds described in this release are
subject to all the risks inherent in the drug development process, and
there can be no assurance that the development of these compounds will
be successful. Forward-looking statements in the press release should be
evaluated together with the many uncertainties that affect Bristol-Myers
Squibb's business, particularly those identified in the cautionary
factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K
for the year ended December 31, 2014, its Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes
no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise.
Copyright Business Wire 2015